Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Am J Health Syst Pharm ; 72(1): 25-38, 2015 Jan 01.
Article in English | MEDLINE | ID: mdl-25511835

ABSTRACT

PURPOSE: The efficacy and safety of the three oral agents approved by the Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis (RRMS) are reviewed. SUMMARY: Limitations to parenteral disease-modifying therapies (DMTs) (interferon beta-1a, interferon beta-1b, and glatiramer acetate) for the treatment of RRMS have been addressed by the approval of three oral DMTs: fingolimod, teriflunomide, and dimethyl fumarate. In clinical trials, each of the oral DMTs was superior to placebo in annualized relapse rate, a key indicator of clinical efficacy, and in neuroradiological efficacy. A reduction in disability progression was evident with higher doses of teriflunomide but was not consistently demonstrated with fingolimod or dimethyl fumarate. Each of the oral DMTs demonstrated acceptable safety in clinical trials, with adverse-effect profiles that differ from injectable agents. The safety of both teriflunomide and dimethyl fumarate is supported by long-term use of related agents for other diseases; however, postmarketing surveillance studies are needed to determine the safety of each of the oral DMTs in patients with RRMS. Dimethyl fumarate seems to have the most innocuous safety profile of the three agents. Fingolimod requires first-dose inpatient monitoring due to cardiac safety concerns and multiple laboratory tests prior to initiation of therapy, while teriflunomide has been associated with hepatotoxicity and teratogenicity. CONCLUSION: With the approval of three oral drugs for RRMS-fingolimod, teriflunomide, and dimethyl fumarate-the therapeutic strategy for RRMS has evolved to include options that are efficacious and appear to have administration advantages over established parenteral treatments.


Subject(s)
Immunosuppressive Agents/therapeutic use , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Administration, Oral , Crotonates/administration & dosage , Crotonates/adverse effects , Crotonates/therapeutic use , Dimethyl Fumarate , Disease Progression , Drug Approval , Fingolimod Hydrochloride , Fumarates/administration & dosage , Fumarates/adverse effects , Fumarates/therapeutic use , Humans , Hydroxybutyrates , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Multiple Sclerosis, Relapsing-Remitting/physiopathology , Nitriles , Propylene Glycols/administration & dosage , Propylene Glycols/adverse effects , Propylene Glycols/therapeutic use , Sphingosine/administration & dosage , Sphingosine/adverse effects , Sphingosine/analogs & derivatives , Sphingosine/therapeutic use , Toluidines/administration & dosage , Toluidines/adverse effects , Toluidines/therapeutic use , United States , United States Food and Drug Administration
2.
Am J Health Syst Pharm ; 70(14): 1250-5, 2013 Jul 15.
Article in English | MEDLINE | ID: mdl-23820463

ABSTRACT

PURPOSE: Preapproval and postapproval availability of published comparative efficacy studies on biological agents approved between 2000 and 2010 was investigated. METHODS: Approval packages published on the Food and Drug Administration (FDA) website were examined for all biological agents approved between 2000 and 2010 to determine if comparative efficacy studies were available at the time of FDA approval. The availability of comparative efficacy studies published subsequent to approval was determined by searching PubMed for randomized, active-controlled experimental or observational study designs that measured efficacy as the primary endpoint and were relevant to the original FDA-approved indication. RESULTS: From 2000 to 2010, 107 biological agents were approved by FDA. Of the biological agents with alternative treatments, 54.6% had comparative efficacy data available at the time of approval. Although standard-reviewed biological agents were more likely to have comparative efficacy trials included in the FDA approval packages than priority-reviewed biological agents, statistically significant differences are unlikely. Subsequent to approval, 58.1% of biological agents had at least one published comparative efficacy trial, representing a 3.5% absolute increase in the availability of comparative efficacy studies since the time of approval. Vaccines and biological agents in the hematologic diseases, oncology, and miscellaneous diseases classes had fewer published postapproval comparative efficacy studies per agent compared with the overall group of biological agents. CONCLUSION: Nearly half of all biological agents approved for marketing between 2000 and 2010 lacked publicly accessible, active-controlled efficacy studies at the time of drug approval; a slightly greater proportion of biological agents had comparative efficacy data published subsequent to their approval.


Subject(s)
Biological Products/therapeutic use , Databases, Factual , Drug Approval , United States Food and Drug Administration/standards , Databases, Factual/standards , Drug Approval/methods , Humans , Randomized Controlled Trials as Topic/standards , Treatment Outcome , United States
3.
P T ; 38(3): 154-60, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23641133

ABSTRACT

Linaclotide (Linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation.

SELECTION OF CITATIONS
SEARCH DETAIL